The inflammatory bowel disease is characterized by a loss of intestinal barrier integrity, which is reversed by the application of bone marrow MSCEXs by increase the IL-10 and TGF-β levels and the decrease in vascular endothelial growth factor (VEGF)-A, TNF-α, the interleukin IL-12, and promotes M2 macrophages activity [209,210] Thus, as a proof of concept, EXs isolated without modifications could be applied as therapeutic devices for treating different diseases. Here, VEGFA is linked to inflammatory bowel disease.